A clinical trial to study the effects of a herbal drug Qurs Mufasil in patients with joint pain (Arthritis)

A placebo controlled double blind randomized trial of Qurse Mufasil in the treatment of Rheumatoid arthritis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2009/091/000746

Enrollment

150

Registered

2009-09-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Qurs Mufasil: 1000 mg daily for 3 months Control Intervention1: Placebo: 1000 mg twice daily for 3 months

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of 20-70 years of age fulfilling the criteria of American College of Rheumatology (ACR) for the diagnosis of Rheumatoid Arthritis, who had never received disease modifying anti/Rheumatoid Drugs (DMARDs). 2.Presence of active disease as defined by the presence of >, 6 tender joints and >; 6 swollen joints.

Exclusion criteria

Exclusion criteria: 1.Patients with concomitant renal/ hepatic insufficiently or sever gastrointestinal insufficiency. 2.Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Reduction in Swollen Joint Count,Tender Joint Count, Intensity of Pain-VAS (0-100), Morning Stiffness and ESRTimepoint: 4,8,12 weeks	—

Secondary

Measure	Time frame
1.ACR20 Response 2.Improvement in quality of life as assessed by HAQ disability scoreTimepoint: 3 months	—

Countries

India

Contacts

Public ContactYasmeen Shamsi

yasmeen.ijum@gmail.com01126059692

Outcome results